Literature DB >> 25665955

SABR in NSCLC--the beginning of the end or the end of the beginning?

Michael Brada1, Anthony Pope2, Michael Baumann3.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25665955     DOI: 10.1016/j.radonc.2015.01.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


× No keyword cloud information.
  4 in total

1.  A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC.

Authors:  Raphaël Jumeau; Édith Filion; Houda Bahig; Toni Vu; Louise Lambert; David Roberge; Robert Doucet; Marie-Pierre Campeau
Journal:  Br J Radiol       Date:  2017-06-07       Impact factor: 3.039

Review 2.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Authors:  Alexander Chi; Haiquan Chen; Sijin Wen; Haijuan Yan; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2017-05-22       Impact factor: 6.280

3.  The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance.

Authors:  Matthew Beasley; Sean Brown; Helen McNair; Corinne Faivre-Finn; Kevin Franks; Louise Murray; Marcel van Herk; Ann Henry
Journal:  Br J Radiol       Date:  2019-04-24       Impact factor: 3.039

4.  The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy-rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial.

Authors:  Housne Begum; Anand Swaminath; Yung Lee; Christine Fahim; Jonathan Bramson; Asghar Naqvi; Yaron Shargall; Christian Finley; Wael Hanna; John Agzarian
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.